BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 23436077)

  • 1. Increased osteoblast and osteoclast indices in individuals with systemic mastocytosis.
    Seitz S; Barvencik F; Koehne T; Priemel M; Pogoda P; Semler J; Minne H; Pfeiffer M; Zustin J; Püschel K; Eulenburg C; Schinke T; Amling M
    Osteoporos Int; 2013 Aug; 24(8):2325-34. PubMed ID: 23436077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone lesions in systemic mastocytosis: Bone histomorphometry and histopathological mechanisms.
    Bouvard B; Pascaretti-Grizon F; Legrand E; Lavigne C; Audran M; Chappard D
    Morphologie; 2020 May; 104(345):97-108. PubMed ID: 32127247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An increased bone mineral density is an adverse prognostic factor in patients with systemic mastocytosis.
    Riffel P; Schwaab J; Lutz C; Naumann N; Metzgeroth G; Fabarius A; Schoenberg SO; Hofmann WK; Valent P; Reiter A; Jawhar M
    J Cancer Res Clin Oncol; 2020 Apr; 146(4):945-951. PubMed ID: 31980928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis.
    Rossini M; Zanotti R; Bonadonna P; Artuso A; Caruso B; Schena D; Vecchiato D; Bonifacio M; Viapiana O; Gatti D; Senna G; Riccio A; Passalacqua G; Pizzolo G; Adami S
    Bone; 2011 Oct; 49(4):880-5. PubMed ID: 21782049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osteoporosis Caused by Systemic Mastocytosis: Prevalence in a Cohort of 8392 Patients with Osteoporosis.
    Gehlen M; Schmidt N; Pfeifer M; Balasingam S; Schwarz-Eywill M; Maier A; Werner M; Siggelkow H
    Calcif Tissue Int; 2021 Dec; 109(6):685-695. PubMed ID: 34223956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolution of urticaria pigmentosa into indolent systemic mastocytosis: abnormal immunophenotype of mast cells without evidence of c-kit mutation ASP-816-VAL.
    Noack F; Escribano L; Sotlar K; Nunez R; Schuetze K; Valent P; Horny HP
    Leuk Lymphoma; 2003 Feb; 44(2):313-9. PubMed ID: 12688351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic criteria and classification of mastocytosis: a consensus proposal.
    Valent P; Horny HP; Escribano L; Longley BJ; Li CY; Schwartz LB; Marone G; Nuñez R; Akin C; Sotlar K; Sperr WR; Wolff K; Brunning RD; Parwaresch RM; Austen KF; Lennert K; Metcalfe DD; Vardiman JW; Bennett JM
    Leuk Res; 2001 Jul; 25(7):603-25. PubMed ID: 11377686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone mastocytosis. A report of nine cases with a bone histomorphometric study.
    de Gennes C; Kuntz D; de Vernejoul MC
    Clin Orthop Relat Res; 1992 Jun; (279):281-91. PubMed ID: 1600667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diminished reliability of tryptase as risk indicator of mastocytosis in older overweight subjects.
    Vos BJ; van der Veer E; van Voorst Vader PC; Mulder AB; van der Heide S; Arends S; Kluin-Nelemans JC; de Monchy JG; van Doormaal JJ; Oude Elberink JN
    J Allergy Clin Immunol; 2015 Mar; 135(3):792-8. PubMed ID: 25129675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis.
    Zanotti R; Bonifacio M; Lucchini G; Sperr WR; Scaffidi L; van Anrooij B; Oude Elberink HN; Rossignol J; Hermine O; Gorska A; Lange M; Hadzijusufovic E; Miething C; Müller S; Perkins C; Shomali W; Elena C; Illerhaus A; Jawhar M; Parente R; Caroppo F; Solomianyi O; Zink A; Mattsson M; Yavuz AS; Panse J; Varkonyi J; Doubek M; Sabato V; Breynaert C; Vucinic V; Schug T; Hägglund H; Wortmann F; Brockow K; Angelova-Fischer I; Belloni Fortina A; Triggiani M; Reiter A; Hartmann K; Malcovati L; Gotlib J; Shoumariyeh K; Niedoszytko M; Arock M; Kluin-Nelemans HC; Bonadonna P; Valent P
    Leukemia; 2022 Feb; 36(2):516-524. PubMed ID: 34545185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Histological characteristics and prevalence of secondary osteoporosis in systemic mastocytosis. A retrospective analysis of 158 cases].
    Delling G; Ritzel H; Werner M
    Pathologe; 2001 Mar; 22(2):132-40. PubMed ID: 11321729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM.
    Alvarez-Twose I; Zanotti R; González-de-Olano D; Bonadonna P; Vega A; Matito A; Sánchez-Muñoz L; Morgado JM; Perbellini O; García-Montero A; De Matteis G; Teodósio C; Rossini M; Jara-Acevedo M; Schena D; Mayado A; Zamò A; Mollejo M; Sánchez-López P; Cabañes N; Orfao A; Escribano L; ;
    J Allergy Clin Immunol; 2014 Feb; 133(2):520-8. PubMed ID: 23921094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification.
    Trizuljak J; Sperr WR; Nekvindová L; Elberink HO; Gleixner KV; Gorska A; Lange M; Hartmann K; Illerhaus A; Bonifacio M; Perkins C; Elena C; Malcovati L; Fortina AB; Shoumariyeh K; Jawhar M; Zanotti R; Bonadonna P; Caroppo F; Zink A; Triggiani M; Parente R; von Bubnoff N; Yavuz AS; Hägglund H; Mattsson M; Panse J; Jäkel N; Kilbertus A; Hermine O; Arock M; Fuchs D; Sabato V; Brockow K; Bretterklieber A; Niedoszytko M; van Anrooij B; Reiter A; Gotlib J; Kluin-Nelemans HC; Mayer J; Doubek M; Valent P
    Allergy; 2020 Aug; 75(8):1927-1938. PubMed ID: 32108361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mastocytosis: state of the art.
    Horny HP; Sotlar K; Valent P
    Pathobiology; 2007; 74(2):121-32. PubMed ID: 17587883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KIT D816V mutation burden does not correlate to clinical manifestations of indolent systemic mastocytosis.
    Broesby-Olsen S; Kristensen T; Vestergaard H; Brixen K; Møller MB; Bindslev-Jensen C;
    J Allergy Clin Immunol; 2013 Sep; 132(3):723-728. PubMed ID: 23587333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The stromal composition of mast cell aggregates in systemic mastocytosis.
    Chiu A; Nanaji NM; Czader M; Gheorghe G; Knowles DM; Chadburn A; Orazi A
    Mod Pathol; 2009 Jul; 22(7):857-65. PubMed ID: 19396155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delineation of patterns of bone marrow mast cell infiltration in systemic mastocytosis: value of CD25, correlation with subvariants of the disease, and separation from mast cell hyperplasia.
    Krokowski M; Sotlar K; Krauth MT; Födinger M; Valent P; Horny HP
    Am J Clin Pathol; 2005 Oct; 124(4):560-8. PubMed ID: 16146815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Vulvar oedema revealing systemic mastocytosis].
    Deveza E; Locatelli F; Girardin M; Valmary-Degano S; Daguindau E; Aubin F; Humbert P; Pelletier F
    Ann Dermatol Venereol; 2015 Nov; 142(11):685-9. PubMed ID: 26003033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An unusual case of systemic mastocytosis associated with chronic lymphocytic leukaemia (SM-CLL).
    Horny HP; Sotlar K; Stellmacher F; Valent P; Grabbe J
    J Clin Pathol; 2006 Mar; 59(3):264-8. PubMed ID: 16505276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Indolent systemic mast cell disease: immunophenotypic characterization of bone marrow mast cells by flow cytometry.
    Bodni RA; Sapia S; Galeano A; Kaminsky A
    J Eur Acad Dermatol Venereol; 2003 Mar; 17(2):160-6. PubMed ID: 12705744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.